Corrigendum to "PEGylated ofloxacin nanoparticles render strong antibacterial activity against many clinically important human pathogens" [Colloids Surf. B: Biointerfaces 132 (2015) 62-70]
Colloids Surf B Biointerfaces. 2019 May 1:177:282-283.
doi: 10.1016/j.colsurfb.2019.01.063.
Epub 2019 Feb 12.
1 Centre for the Research and Technology of Agro-Environment and Biological Sciences (CITAB), University of Minho, Portugal.
2 Life and Health Sciences Research Institute (ICVS), School of Health Sciences, University of Minho, Portugal; ICVS/3B's - PT Government Associate Laboratory, Braga/Guimarães, Portugal.
3 Consorzio Mario Negri Sud, Department of Translational Pharmacology, Santa Maria Imbaro, Italy.
4 Department of Pharmaceutics, PSG College of Pharmacy, Coimbatore, Tamil Nadu, India.
5 Life and Health Sciences Research Institute (ICVS), School of Health Sciences, University of Minho, Portugal; ICVS/3B's - PT Government Associate Laboratory, Braga/Guimarães, Portugal; Regenerative Medicine Program, Departamento de Ciências Biomédicas e Medicina, Universidade do Algarve, Faro, Portugal; IBB-Institute for Biotechnology and Bioengineering, Centro de Biomedicina Molecular e Estrutural, Universidade do Algarve, Faro, Portugal.
6 Centre for the Research and Technology of Agro-Environment and Biological Sciences (CITAB), University of Minho, Portugal. Electronic address: [email protected].